Parabon NanoLabs Receives Phase II SBIR Grant From NSF
To Continue Development Of New Cancer Therapeutics

New Anticancer Molecules Engineered to Self-Assemble Using Synthetic DNA

1 September 2010

Parabon® NanoLabs has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation to continue to design and build new drug compounds. Building on the success of its Phase I project, Parabon will advance the development of new drug compounds for the treatment of glioma (brain tumors), one of the deadliest forms of cancer. Parabon is developing compounds using self-assembling DNA nanostructures functionalized with molecular subcomponents with the purpose of targeting and destroying malignant tumors. These drug compounds are designed and constructed using the Parabon Essemblix Drug Development Platform — a powerful combination of proprietary computer-aided design (CAD) software for designing macromolecules and nanoscale fabrication technology. Essemblix enables molecular engineering in a novel and revolutionary fashion, replacing the current paradigm of "drug discovery," which is slow, unpredictable and costly, with a new "drug design" paradigm that is rapid, deliberate and more affordable.

Click here to learn more about the project and award.

- - - - -

For more information contact, 703.689.9689 x250